WilmerHale Represents Verve Therapeutics in $94M Series B Financing
On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing, led by Wellington Management Company and co-led by Casdin Capital, existing investors. New investors in the funding included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, and a US-based, healthcare-focused fund, alongside additional existing investors GV and Biomatics.
Proceeds from the financing will be used to advance the company’s of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.
The WilmerHale team representing Verve includes Lia Der Marderosian, Timothy Kulis and Meghan Muncey.